MYH14 and dilated cardiomyopathy: Indeed, myosin mutations are associated with cardiomyopathies with different phenotypes, including hypertrophic (HCM) and dilated cardiomyopathy (DCM), and myosin modulators could be potentially used to counteract their damaging effect, with specific drugs tailored for specific mutations [1, 4, 5].